Agenus to Participate in Oppenheimer 34th Annual Healthcare Life Sciences Conference

 

Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced that Dr. Garo Armen, Chairman and CEO, will participate in a fireside chat and investor one-on-ones at the upcoming Oppenheimer Healthcare Conference on February 13th - 14th. The fireside chat will take place at 8:00 a.m. ET on February 14th.

A live webcast and replay of the fireside chat will be accessible on the company’s website at https://investor.agenusbio.com/events-and-presentations.

About Agenus

Agenus is a leading immuno-oncology company targeting cancer and infectious diseases with a comprehensive pipeline of immunological agents. The company’s mission is to expand patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeutics, adoptive cell therapies (through MiNK Therapeutics) and adjuvants (through SaponiQx). Agenus is headquartered in Lexington, MA. For more information, visit www.agenusbio.com or @agenus_bio. Information that may be important to investors will be routinely posted on our website and social media channels.

Contacts

More News

View More

Recent Quotes

View More
Symbol Price Change (%)
AMZN  248.40
-0.62 (-0.25%)
AAPL  258.76
-0.07 (-0.03%)
AMD  255.50
+0.43 (0.17%)
BAC  54.27
+0.91 (1.72%)
GOOG  330.33
-0.25 (-0.08%)
META  672.07
+9.58 (1.45%)
MSFT  402.74
+9.63 (2.45%)
NVDA  198.37
+1.86 (0.95%)
ORCL  170.78
+7.78 (4.77%)
TSLA  369.89
+5.69 (1.56%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.